Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.52 |
| ▸ | BCHE known ✓ | P06276 | 3/20 | 0.51 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.51 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.50 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.46 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4432892 | 1.00 | GAA (0.52) | GAAMEN1KMT2ABCHEACHE | |
| Hydrochloric Acid SCHEMBL4425500 | 1.00 | GAA (0.52) | GAAMEN1KMT2ABCHEACHE | |
| SCHEMBL3810424 | 0.98 | GAA (0.54) | GAAMEN1KMT2ABCHEACHE | |
| SCHEMBL4427076 | 0.98 | GAA (0.54) | GAAMEN1KMT2ABCHEACHE | |
| SCHEMBL3810502 | 0.98 | GAA (0.54) | GAAMEN1KMT2ABCHEACHE | |
| Hydrochloric Acid SCHEMBL4846915 | 0.90 | GAA (0.61) | GAAMEN1KMT2ABCHEACHE | |
| Hydrochloric Acid SCHEMBL2673496 | 0.89 | MEN1 (0.58) | MEN1KMT2ABCHEACHEBACE1 | |
| Hydrochloric Acid SCHEMBL11533737 | 0.89 | MEN1 (0.58) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL25373516 | 0.88 | GAA (0.62) | GAAMEN1KMT2ABCHEACHE | |
| SCHEMBL4848550 | 0.88 | GAA (0.62) | GAAMEN1KMT2ABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7390830-B1 | Remedies or prophylactics for diseases in association with chemokines | TEIJIN LIMITED (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20070249701-A1 | Cyclic amine CCR5 receptor antagonists | TEIJIN LIMITED | 2007-10-25 | — | — | US | disclosed |
| EP-1238970-B9 | CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS | TEIJIN LTD (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | TEIJIN PHARMA LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1238970-B1 | CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS | TEIJIN LTD (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1179341-B1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LTD (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1553085-A1 | Cyclic amine derivatives and their use as drugs | TEIJIN LIMITED (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1535909-A2 | Cyclic amine derivatives and their use as drugs | TEIJIN LIMITED (JP) | 2005-06-01 | — | — | EP | disclosed |
| CN-1433402-A | Cycloamine CCR5 receptor antagonists | TEIJIN LTD (JP) | 2003-07-30 | — | — | CN | disclosed |
| CN-1384743-A | Remedies or preventives for diseases in association with chemokines | TEIJIN LTD (JP) | 2002-12-11 | — | — | CN | disclosed |
| CN-1376063-A | Cyclic amine CCR3 antagonisis | TEIJIN LTD (JP) | 2002-10-23 | — | — | CN | disclosed |
| US-6451842-B1 | Cyclic amine derivatives and their use as drugs | DUPONT PHARMACEUTICALS COMPANY | 2002-09-17 | — | — | US | disclosed |
| EP-1238970-A1 | CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS | TEIJIN LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6410566-B1 | ATHEROSCLEROSIS; ANTIARTHRITIC AGENTS | TEIJIN LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1201239-A1 | CYCLIC AMINE CCR3 ANTAGONISTS | TEIJIN LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-6362177-B1 | INHIBITION OF CHEMOKINE BINDING | TEIJIN LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1179341-A1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LIMITED (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | CCR5, CCR2, CCR1 | GAA 4574/4885BCHE 2388/4885ACHE 3567/4885 |
| US-20070249701-A1 | Cyclic amine CCR5 receptor antagonists | CCR5, CCR7, CCR2 | GAA 4275/4885BCHE 2857/4885ACHE 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.